NTLA-2001
Intellia Therapeutics
['crispr']
#attr news: today, at the scientific sessions, intellia presented additional interim results from its ongoing phase 1 study of ntla-2001, an investigational, in vivo #crispr #genomeediting therapy. learn more: #aha22 
We're a #GenomeEditing company, developing novel, potentially curative therapeutics leveraging #CRISPR-based technologies. Guidelines: https://t.co/u2gHl9Tmgr